Kenvue Inc（KVUE）の決算・業績分析
Kenvue Incの2025年有価証券報告書をAI分析。売上高$15.1B(-2.1%)。営業利益$2.4B。Materials。
目次
Kenvue Incの2025年度 業績サマリー
Kenvue Inc（証券コード: KVUE）の2025年度決算・業績分析。売上高は$15.1B（前年比-2.1%）。営業利益は$2.4B（前年比+31.1%）。純利益は$1.5B（前年比+42.7%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
Kenvue Incの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Kenvue's FY2024 revenue declined slightly to $14.9B (-0.7% YoY) (XBRL), while EBITDA margin remained strong at 22.2% (XBRL).
- Operating income fell 8.4% YoY to $2.7B (XBRL), reflecting broader industry pressures despite robust gross margin of 55.4% (XBRL).
- The company maintained strong liquidity with $1.2B cash (XBRL) and a conservative debt-to-equity ratio of 0.81x (XBRL).
Kenvue Incの売上高変化の要因
- •FY2024 revenue totaled $14.9B (-0.7% YoY) (XBRL), with historical time series showing a slight decline from $15.1B in FY2023 to $14.9B in FY2024, followed by a projected increase to $15.4B in FY2025 (XBRL). Segment-specific revenue details are not disclosed in the provided data (XBRL). Growth drivers remain unclear due to limited segment and geographic breakdowns (XBRL), though the company's focus on digital engagement and brand innovation is highlighted in the 10-K.
Kenvue Incの営業利益変化の要因
- •Profitability metrics show mixed performance: gross margin remained stable at 55.4% (XBRL), but operating margin declined to 17.9% (-8.4% YoY) (XBRL). Net margin held steady at 13.8% (XBRL). Over five years, revenue grew at a 1.3% CAGR (XBRL), while operating income and net income declined at -7.2% and -10.5% CAGR, respectively (XBRL). EBITDA of $3.3B (22.2% margin) (XBRL) reflects efficient cost management despite operating income declines.
Kenvue Incの事業リスクと対応
Reputation damage from negative publicity could harm brand loyalty (10-K).
Intense competition from multinational and generic products threatens market share (10-K).
Challenges in innovating and adapting to changing consumer preferences (10-K).
Global expansion risks due to operational and legal complexities (10-K).
Uncertainty in AI regulation and deployment impacts business operations (10-K).
Regulatory compliance risks (tax, ESG, data privacy) and geopolitical impacts (10-K).
Talc-related liabilities from past sales are noted as a legal risk (10-K).
Kenvue Incの事業内容
Kenvue Inc. operates as a global consumer health company, generating revenue through the sale of self-care, skin health, beauty, and essential health products across 165+ countries (10-K). Key segments include Self Care (e.g., Tylenol®, Listerine®), Skin Health and Beauty (e.g., Neutrogena®, Aveeno®), and Essential Health (e.g., BAND-AID®, Zyrtec®) (10-K). The company leverages its portfolio of iconic, science-backed brands and a digital strategy to drive sales, with no significant customer concentration reported (10-K). Competitive advantages include global scale, brand trust, and an ESG-focused strategy (10-K).
Kenvue IncのAI業績分析レポート（2024年度）
Kenvue Inc. (KVUE) FY2024 Annual Report Analysis
Highlights
Business Overview
Kenvue operates as a global consumer health company, generating revenue through self-care, skin health, beauty, and essential health products (10-K). Key segments include Self Care (e.g., Tylenol®), Skin Health and Beauty (e.g., Neutrogena®), and Essential Health (e.g., BAND-AID®) (10-K). The company leverages iconic brands and a digital strategy, with no significant customer concentration (10-K). Competitive advantages include global scale, brand trust, and an ESG-focused strategy (10-K).
Revenue Analysis
FY2024 revenue totaled $14.9B (-0.7% YoY) (XBRL), with historical time series showing a slight decline from $15.1B in FY2023 to $14.9B in FY2024, followed by a projected increase to $15.4B in FY2025 (XBRL). Segment-specific revenue details are not disclosed (XBRL). Growth drivers remain unclear due to limited segment and geographic breakdowns (XBRL), though the company's focus on digital engagement and brand innovation is highlighted in the 10-K.
Profitability Analysis
Profitability metrics show mixed performance: gross margin remained stable at 55.4% (XBRL), but operating margin declined to 17.9% (-8.4% YoY) (XBRL). Net margin held steady at 13.8% (XBRL). Over five years, revenue grew at a 1.3% CAGR (XBRL), while operating income and net income declined at -7.2% and -10.5% CAGR, respectively (XBRL). EBITDA of $3.3B (22.2% margin) (XBRL) reflects efficient cost management despite operating income declines.
Balance Sheet Analysis
Kenvue's balance sheet shows strong equity with a 73.6% equity ratio (XBRL) and a debt-to-equity ratio of 0.81x (XBRL). Total assets increased to $27.9B in FY2024 (XBRL), while total equity rose to $20.5B (XBRL). Liquidity is supported by $1.2B in cash (XBRL) and a current ratio of 1.12x (XBRL). Return on equity (ROE) of 10.1% (XBRL) and ROA of 7.4% (XBRL) indicate moderate capital efficiency.
Cash Flow Analysis
Operating cash flow totaled $2.5B (XBRL), with free cash flow of $2.1B after $375M in CapEx (XBRL). Investing cash flow was -$390M (XBRL), while financing cash flow was -$1.6B (XBRL). No dividends or share repurchases were paid in FY2024 (XBRL). CapEx intensity remained low at 2.5% (XBRL), with R&D expenses at $375M (XBRL).
Working Capital Analysis
Working capital efficiency metrics include a 16-day cash conversion cycle (CCC) (XBRL), with receivables days at 51, inventory days at 101, and payables days at 136 (XBRL).
Risks
Outlook
N/A. Management guidance and forward-looking trends are not explicitly mentioned in the 10-K or XBRL data.
Historical Time Series
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | 15.1B | 14.9B | 15.4B |
| Operating Income | 2.9B | 2.7B | 2.5B |
| Net Income | 2.1B | 2.1B | 1.7B |
| Total Assets | 27.3B | 27.9B | 25.6B |
| Total Equity | 18.4B | 20.5B | 20.0B |
| Operating Cash Flow | 334M | 2.5B | 3.2B |
Materialsの企業一覧
Kenvue Incと同じ「Materials」セクターの企業